Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation
- 9 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 56 (10), 2471-2476
- https://doi.org/10.1038/s41409-021-01362-2
Abstract
Eltrombopag has shown efficacy in the treatment of thrombocytopenia and poor graft function (PGF) after allogeneic hematopoietic cell transplantation (HCT) in retrospective observational studies, but is not approved for this indication. The cost of this drug is also a major concern in publicly funded health care systems. We collected data about patients who received eltrombopag for thrombocytopenia or PGF after HCT. Post-HCT thrombocytopenia, PGF, and eltrombopag response were defined as per previously published criteria. Primary outcome was treatment efficacy and secondary outcome was cost comparison between estimated treatment cost prior to and after initiation of eltrombopag. Seventeen patients (males 70.6%; median age = 58) received eltrombopag. Isolated thrombocytopenia was present in 11.8% (n = 2) patients while PGF was present in 88.2% (n = 15) of patients. After 8 weeks of treatment at the maximum dose of 150 mg orally daily, overall response rate (ORR) was seen in 76.5% (13/17) of patients: complete response (CR) in 10/13 patients and partial response (PR) in 3/13 patients. The use of eltrombopag was associated with an overall decrease in the total weekly care costs (5021 vs 2,524 CA$; P = 0.04). Thus, Eltrombopag is an efficacious and possibly cost-effective therapy for thrombocytopenia and PGF after allogeneic HCT.Keywords
This publication has 39 references indexed in Scilit:
- Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2019
- Risk Factors and Impact of Secondary Failure of Platelet Recovery After Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2016
- CD34 Selected Cells for the Treatment of Poor Graft Function after Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2014
- Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation – frequency and outcomesBone Marrow Transplantation, 2004
- Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplantBone Marrow Transplantation, 2003
- Secondary failure of platelet recovery after hematopoietic stem cell transplantationTransplantation and Cellular Therapy, 2001
- Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell doseBritish Journal of Haematology, 2001
- Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor ProgramBlood, 2000
- The Problem of Thrombocytopenia after Hematopoietic Stem Cell TransplantationThe International Journal of Cell Cloning, 1996
- Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromesBlood, 1985